| Daniel B Brown, DO | |
|
1025 N Douty St, Emergency Department, Hanford, CA 93230-3722 | |
| (559) 583-2100 | |
| Not Available |
| Full Name | Daniel B Brown |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 32 Years |
| Location | 1025 N Douty St, Hanford, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215981535 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 2OA6402 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaweah Delta Medical Center | Visalia, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaweah Delta Health Care District | 6608778790 | 53 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
One of the biggest health problems facing children today is pediatric obesity. Getting to the core of what is causing obesity - and how the U.S. can tackle this problem - is the focus of a topic symposium at the Pediatric Academic Societies (PAS) annual meeting in Boston.
A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.
› Verified 1 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
One of the biggest health problems facing children today is pediatric obesity. Getting to the core of what is causing obesity - and how the U.S. can tackle this problem - is the focus of a topic symposium at the Pediatric Academic Societies (PAS) annual meeting in Boston.
A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.
› Verified 1 days ago
| Entity Name | Kaweah Delta Health Care District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790795458 PECOS PAC ID: 6608778790 Enrollment ID: O20050408001146 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
One of the biggest health problems facing children today is pediatric obesity. Getting to the core of what is causing obesity - and how the U.S. can tackle this problem - is the focus of a topic symposium at the Pediatric Academic Societies (PAS) annual meeting in Boston.
A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.
› Verified 1 days ago
| Entity Name | Kaweah Delta Health Care District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326704529 PECOS PAC ID: 6608778790 Enrollment ID: O20110914000795 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
One of the biggest health problems facing children today is pediatric obesity. Getting to the core of what is causing obesity - and how the U.S. can tackle this problem - is the focus of a topic symposium at the Pediatric Academic Societies (PAS) annual meeting in Boston.
A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel B Brown, DO 4551 Glencoe Ave, Suite 260, Marina Del Rey, CA 90292-6385 Ph: (310) 301-2030 | Daniel B Brown, DO 1025 N Douty St, Emergency Department, Hanford, CA 93230-3722 Ph: (559) 583-2100 |
News Archive
Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.
The University of Texas at Arlington received more than $2.1 million in grants from the Cancer Prevention & Research Institute of Texas to support the University's flourishing cancer research programs.
Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.
One of the biggest health problems facing children today is pediatric obesity. Getting to the core of what is causing obesity - and how the U.S. can tackle this problem - is the focus of a topic symposium at the Pediatric Academic Societies (PAS) annual meeting in Boston.
A new method of vaccine design, called the Multiple Antigen Presentation System, may result in vaccines that bring together the benefits of whole-cell and acellular or defined subunit vaccination.
› Verified 1 days ago
Dr. Joseph Ginejko, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 Greenfield Ave, Hanford, CA 93230 Phone: 559-582-9000 | |
Scott Bowen, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 Greenfield Ave, Emergency Dept., Hanford, CA 93230 Phone: 559-582-9000 | |
Jaclyn Marie Wood, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 115 Mall Dr, Hanford, CA 93230 Phone: 559-537-0550 | |
Milton Teske, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 115 Mall Dr, Adventist Medical Center Hanford - Emergency Dept, Hanford, CA 93230 Phone: 559-537-0550 | |
Edward Wargo, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1025 N Douty St, Emergency Dept., Hanford, CA 93230 Phone: 559-583-2100 | |
David A. Smith, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1025 N Douty St, Emergency Department, Hanford, CA 93230 Phone: 559-583-2100 |